OBJECTIVE: No therapy except liver transplantation currently exists for patients with acute liver failure (ALF). The aim of this study was to determine whether pharmacologic mobilization of endogenous hematopoietic stem cells (HSCs) can aid in liver repair and improve survival in an animal model of ALF. METHODS: Rodents were treated with a single near-lethal intraperitoneal injection of carbon tetrachloride (CCl4). After 12 hours, animals were randomized to receive plerixafor and granulocyte colony-stimulating factor (G-CSF), agents known to mobilize marrow-derived stem cells, or saline vehicle injection. Mice were observed for survival, and serial assessment of liver injury by serum transaminase measurements, and histologic analysis was performed. RESULTS: In our ALF model, 7-day survival after injection of CCl4 was 25%. Administration of plerixafor and G-CSF following CCl4 resulted in 87% survival (n = 8, P < 0.05). On serial histopathologic analysis, animals treated with plerixafor and G-CSF demonstrated less hepatic injury compared with control animals. Evaluation of peripheral blood demonstrated an increase in circulating HSCs in response to plerixafor and G-CSF, and immunostaining suggested the infiltration of HSCs into the hepatic parenchyma after stem cell mobilization. CONCLUSIONS: Our results suggest a possible new treatment strategy for patients with ALF, a group for whom either liver transplantation or death is frequently the outcome. Pharmacologic agents that mobilize HSCs may lead to an infiltration of the injured liver with cells that may participate in or expedite liver regeneration. This therapy has the potential to avert liver transplantation in some patients with ALF and may be of benefit in a wide variety of medical and surgical patients with liver injury.
OBJECTIVE: No therapy except liver transplantation currently exists for patients with acute liver failure (ALF). The aim of this study was to determine whether pharmacologic mobilization of endogenous hematopoietic stem cells (HSCs) can aid in liver repair and improve survival in an animal model of ALF. METHODS: Rodents were treated with a single near-lethal intraperitoneal injection of carbon tetrachloride (CCl4). After 12 hours, animals were randomized to receive plerixafor and granulocyte colony-stimulating factor (G-CSF), agents known to mobilize marrow-derived stem cells, or saline vehicle injection. Mice were observed for survival, and serial assessment of liver injury by serum transaminase measurements, and histologic analysis was performed. RESULTS: In our ALF model, 7-day survival after injection of CCl4 was 25%. Administration of plerixafor and G-CSF following CCl4 resulted in 87% survival (n = 8, P < 0.05). On serial histopathologic analysis, animals treated with plerixafor and G-CSF demonstrated less hepatic injury compared with control animals. Evaluation of peripheral blood demonstrated an increase in circulating HSCs in response to plerixafor and G-CSF, and immunostaining suggested the infiltration of HSCs into the hepatic parenchyma after stem cell mobilization. CONCLUSIONS: Our results suggest a possible new treatment strategy for patients with ALF, a group for whom either liver transplantation or death is frequently the outcome. Pharmacologic agents that mobilize HSCs may lead to an infiltration of the injured liver with cells that may participate in or expedite liver regeneration. This therapy has the potential to avert liver transplantation in some patients with ALF and may be of benefit in a wide variety of medical and surgical patients with liver injury.
Authors: Theresa Hahn; John R Wingard; Kenneth C Anderson; William I Bensinger; James R Berenson; Greg Brozeit; Joseph R Carver; Robert A Kyle; Philip L McCarthy Journal: Biol Blood Marrow Transplant Date: 2003-01 Impact factor: 5.742
Authors: Hüseyin Ince; Michael Petzsch; Hans Dieter Kleine; Heike Eckard; Tim Rehders; Detlev Burska; Stephan Kische; Mathias Freund; Christoph A Nienaber Journal: Circulation Date: 2005-08-30 Impact factor: 29.690
Authors: Antonio Maria Leone; Sergio Rutella; Giuseppina Bonanno; Anna Maria Contemi; Daniela G de Ritis; Maria Benedetta Giannico; Antonio G Rebuzzi; Giuseppe Leone; Filippo Crea Journal: Int J Cardiol Date: 2005-07-26 Impact factor: 4.164
Authors: Neal Flomenberg; Steven M Devine; John F Dipersio; Jane L Liesveld; John M McCarty; Scott D Rowley; David H Vesole; Karin Badel; Gary Calandra Journal: Blood Date: 2005-05-12 Impact factor: 22.113
Authors: Zhaoli Sun; Xiuying Zhang; Jayme E Locke; Qizhi Zheng; Shingo Tachibana; Anna Mae Diehl; George Melville Williams Journal: Hepatology Date: 2009-02 Impact factor: 17.425
Authors: Hyeon Tae Kang; Dae Won Jun; Kiseok Jang; Jeong-Kyu Hoh; Jai Sun Lee; Waqar Khalid Saeed; Yeon Ji Chae; Jin Ho Lee Journal: Dig Dis Sci Date: 2018-11-12 Impact factor: 3.199
Authors: Hai-Jian Sun; Jian Chen; Hao Zhang; Bing Ni; Jennifer C van Velkinburgh; Yao Liu; Yu-Zhang Wu; Xia Yang Journal: Immunol Res Date: 2017-10 Impact factor: 2.829
Authors: Yedidya Saiman; JingJing Jiao; M Isabel Fiel; Scott L Friedman; Costica Aloman; Meena B Bansal Journal: Hepatol Res Date: 2014-10-07 Impact factor: 4.288